13F Holdings
中文EN

CLLS Cellectis S.A. IFRS

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1627281 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY75.8%
TTM net income YoY-83.9%
TTM EPS YoY-63.4%
Revenue 3-yr CAGR56.1%
Net income 3-yr CAGR—

Margins

Gross margin100.0%
Operating margin-45.3%
Net margin-92.7%
FCF margin-57.2%
EBITDA margin-17.8%

Returns

ROE-65.3%
ROA-19.1%
ROIC (approx.)-2,430.7%
Asset turnover0.21x

Leverage & solvency

Liabilities / assets76.6%
Debt / equity0.00x
Current ratio—
Interest coverage-0.65x

Cash quality & payout

Operating cash flow / net income0.58x
Accruals ratio-8.0%
Payout ratio—
Capex / revenue3.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31 · USDFY20242024-12-31 · USDFY20232023-12-31 · USDFY20222022-12-31 · USDFY20212021-12-31 · USD
Income statement
Revenue$72.95M$41.51M$755,000$19.17M$30.35M
Cost of revenue$0$0$737,000$1.77M$1.84M
Gross profit$72.95M$41.51M$18,000$17.40M$28.50M
R&D expense$93.52M$90.54M$87.65M$97.50M$117.84M
SG&A expense$19.79M$19.09M$16.81M$17.49M$22.88M
Operating income-$33.08M-$59.55M-$97.30M-$89.67M-$103.48M
Interest expense$51.06M$21.61M$40.64M$17.82M$6.49M
Pretax income-$68.02M-$36.76M-$116.46M-$98.60M-$96.75M
Income tax-$423,000$0$371,000$87,000$0
Net income-$67.59M-$36.76M-$101.06M-$106.14M-$114.20M
EBITDA-$13.01M-$39.71M-$78.78M-$71.23M-$89.33M
EPS (basic)-0.67-0.41-1.77-2.33-2.55
EPS (diluted)-0.67-0.41-1.77-2.33-2.55
Weighted avg. shares (diluted)100.28M90.57M57.01M45.55M44.82M
Balance sheet
Cash & equivalents$61.53M$143.25M$136.71M$93.22M$185.64M
Short-term investments$144.80M$115.80M———
Receivables$14.40M$6.71M$569,000$772,000$20.36M
Inventory———$0$0
Current assets———$122.04M$225.43M
PP&E, netmay include right-of-use assets (IFRS)$38.79M$45.90M$54.68M$63.62M$78.85M
Intangibles$535,000$1.12M———
Total assets$324.72M$383.54M$334.27M$261.22M$382.08M
Current liabilities$145.75M$166.27M$155.14M$48.13M$49.35M
Total liabilities$248.82M$252.51M$249.57M$135.28M$145.60M
Shareholders' equity$75.90M$131.03M$84.69M$117.97M$221.29M
Shares outstanding100.34M100.09M71.75M45.68M45.48M
Cash flow statement
Operating cash flow-$39.40M$22.99M-$24.75M-$87.44M-$104.56M
Capital expenditure$2.36M$2.58M$1.07M$2.43M$18.54M
Free cash flow-$41.76M$20.41M-$25.82M-$89.88M-$123.11M
Investing cash flow-$29.48M-$102.81M-$15.51M-$2.76M$7.28M
Financing cash flow-$16.76M$89.11M$82.86M$1.15M$47.52M
Depreciation & amortization$20.06M$19.85M$18.52M$18.43M$14.16M
Stock-based compensation$6.11M$3.17M$5.23M$6.04M$11.49M

Free plan shows the latest 5 periods; Pro shows all 12 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.